奥马珠单抗治疗2例高水平IgE过敏性哮喘患儿的用药监护  

Drug monitoring of omalizumab in treatment of 2 children with high level IgE allergic asthma

作　　者：曾娜 王超[1] 孙华君 马丽平 董晓艳 ZENG Na;WANG Chao;SUN Huajun;MA Liping;DONG Xiaoyan(Shanghai Children’s Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200062,China;Shanghai East Hospital,Shanghai 200120,China)

机构地区：[1]上海市儿童医院,上海交通大学医学院附属儿童医院,上海200062 [2]上海市东方医院,上海200120

出　　处：《药学实践杂志》2022年第4期368-371,共4页Journal of Pharmaceutical Practice

基　　金：上海市卫生和计划生育委员会科研课题(20184Y0001)。

摘　　要：目的探讨奥马珠单抗对高水平IgE过敏性哮喘患儿的临床疗效和安全性。方法回顾性分析2020年8月至2021年5月期间,上海市儿童医院呼吸科收治的应用奥马珠单抗治疗的2例过敏性哮喘患儿的临床资料,并在结束治疗后进行定期药学随访,分析奥马珠单抗治疗剂量和疗程、治疗效果及药物不良反应情况。结果2例患儿在接受奥马珠单抗治疗后哮喘症状控制满意,减少哮喘治疗过程中吸入激素使用剂量,鼻部症状减轻。2例患儿共接受奥马珠单抗皮下注射20次,未见不良反应,在结束治疗后定期药学随访,结果显示,患儿身体状况良好。结论奥马珠单抗用于高水平IgE过敏性哮喘患儿的治疗,可以改善哮喘控制症状,长期安全性良好,但其合适的用药剂量和疗程尚需进一步经验积累。Objective To explore the clinical efficacy and safety of the omalizumab treatment in children with high level IgE allergic asthma.Methods The clinical data of 2 children with allergic asthma treated with omalizumab in the Departemnt of Respiratory Medicine of Shanghai Children’s Hospital from August 2020 to May 2021 were retrospectively analyzed,and they had regular follow-up after end of treatment.The dosage and course of treatment,therapeutic effect and adverse drug reactions of omalizumab were analyzed.Results After receiving omalizumab treatment,asthma symptoms were well controlled,the dosage of inhaled corticosteroids during asthma treatment were reduced and nasal symptoms were relieved.20 subcutaneous injections were received by 2 children,and no adverse reactions were found.After the treatment,regular pharmaceutical follow-up showed that the children were in good health.Conclusion Omalizumab is suitable for high level IgE allergic asthma and can improve asthma control symptoms with good long-term safety.However,the appropriate dosage and course of treatment still need further experience accumulation.

关 键 词：奥马珠单抗 儿童 过敏性哮喘 高水平IgE 疗效 不良反应 

分 类 号：R96[医药卫生—药理学]